Reports related to this article:
Project(s): View 3 related projects in PECWeb
Plant(s): View 3 related plants in PECWeb
en
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Scattered throughout North America are 205 reported new-facility builds in the Pharmaceutical-Biotech Industry, according to Industrial Info's Pharmaceutical-Biotech Online Database. The sites represent a potential total capital investment of $18.5 billion, which translates to a per-site average of about $90 million. The "potential" investment for each site includes initial construction, as well as any reported planned future expansions and subsequent phases.
Projections call for the new-build sites to eventually employ more than 40,000. The projects are in various stages of planning, ranging from early market analysis to actual construction. Some of the projects are grassroot, new from the ground up, while others--the "additions"--include reconfiguration and/or renovations of newly acquired facilities. These additions establish the new company's first laboratory or manufacturing operations at that particular location.
Click on the image at right to see a graph detailing new-build projects in the North American Pharmaceutical-Biotech Industry by region.
The projects range from a $1 million investment to construct a small startup plant, to a $1.8 billion mega-plant. A number of the projects are sourced out of the public sector, with many benefiting from federal or state dollars. While many of the facilities are research-based at this point, there is a definite manufacturing presence on the list.
The largest of the planned sites is the nearly $2 billion plan by Novo Nordisk AS (NYSE:NVO) (Bagsvaerd, Denmark) to construct a plant in Clayton, North Carolina. When complete, the site will produce the active pharmaceutical ingredient (API) for use in the production of insulin.
In Boston, Brigham and Women's Hospital is building the $450 million Research Building for the Future. Construction began in 2013; when complete in 2016, the site will focus on neuroscience and regenerative medicine. The project team includes NBBJ Architects (Boston, Massachusetts) and Suffolk Construction (Boston).
Another large project is Procter & Gamble's (NYSE:PG) (Cincinnati, Ohio) decision to construct a $350 million Beauty Innovation Center in Mason, Ohio. The massive, 500,000-square-foot facility will consolidate and expand research and pilot-scale manufacturing to serve the company's hair care, skin care, and other personal care and grooming lines. Construction on the 500,000-square-foot facility began in July, and it is expected to be complete in 2017. The project consolidates and expands the company's product development and testing capacity.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and ten international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
Projections call for the new-build sites to eventually employ more than 40,000. The projects are in various stages of planning, ranging from early market analysis to actual construction. Some of the projects are grassroot, new from the ground up, while others--the "additions"--include reconfiguration and/or renovations of newly acquired facilities. These additions establish the new company's first laboratory or manufacturing operations at that particular location.
Click on the image at right to see a graph detailing new-build projects in the North American Pharmaceutical-Biotech Industry by region.The projects range from a $1 million investment to construct a small startup plant, to a $1.8 billion mega-plant. A number of the projects are sourced out of the public sector, with many benefiting from federal or state dollars. While many of the facilities are research-based at this point, there is a definite manufacturing presence on the list.
The largest of the planned sites is the nearly $2 billion plan by Novo Nordisk AS (NYSE:NVO) (Bagsvaerd, Denmark) to construct a plant in Clayton, North Carolina. When complete, the site will produce the active pharmaceutical ingredient (API) for use in the production of insulin.
In Boston, Brigham and Women's Hospital is building the $450 million Research Building for the Future. Construction began in 2013; when complete in 2016, the site will focus on neuroscience and regenerative medicine. The project team includes NBBJ Architects (Boston, Massachusetts) and Suffolk Construction (Boston).
Another large project is Procter & Gamble's (NYSE:PG) (Cincinnati, Ohio) decision to construct a $350 million Beauty Innovation Center in Mason, Ohio. The massive, 500,000-square-foot facility will consolidate and expand research and pilot-scale manufacturing to serve the company's hair care, skin care, and other personal care and grooming lines. Construction on the 500,000-square-foot facility began in July, and it is expected to be complete in 2017. The project consolidates and expands the company's product development and testing capacity.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, five offices in North America and ten international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities.
